With over 20 years on the market, droxidopa has proven to have few [[Adverse effect|side effect]]s of which most are mild. The most common side effects reported in clinical trials include headache, dizziness nausea, hypertension and fatigue.<ref>{{cite journal

 
| first1     = Horacio

 
| last1      = Kaufmann

 
| first2     = Roy

 
| last2      = Freeman

 
| first3     = Italo

 
| last3      = Biaggioni

 
| first4     = Phillip

 
| last4      = Low

 
| first5     = Simon

 
| last5      = Pedder

 
| first6     = L. Arthur

 
| last6      = Hewitt

 
| first7     = Joe

 
| last7      = Mauney

 
| first8     = Michael

 
| last8      = Feirtag

 
| first9     = Christopher J.

 
| last9      = Mathias

 
| title      = Droxidopa for neurogenic orthostatic hypotension: a randomized placebo-controlled Phase 3 trial

 
| journal    = Neurology

 
| date       = 2014

 
| volume     = 83

 
| issue      = 4

 
| pages      = 328–335

 
| doi        = 10.1212/WNL.0000000000000615

 
| pmid       = 24944260

 
| pmc=4115605

 
}}</ref><ref>{{cite journal

 
| first1     = Robert A.

 
| last1      = Hauser

 
| first2     = Stuart

 
| last2      = Isaacson

 
| first3     = Jerome P.

 
| last3      = Lisk

 
| first4     = L. Arthur

 
| last4      = Hewitt

 
| first5     = Gerry

 
| last5      = Rowse

 
| title      = Droxidopa for the Short-Term Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Parkinson's Disease (nOH306B)

 
| journal    = Movement Disorders

 
| date       = 2015

 
| volume     = 30

 
| issue      = 5

 
| pages      = 646–654

 
| doi        = 10.1002/mds.26086

 
}}</ref><ref name="accessdata.fda.gov">http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/203202lbl.pdf</ref><ref name="accessdata.fda.gov"/>

 

